Diseases: Pitt collaborative receives $7 million for COVID-19 outpatient convalescent plasma therapy

IMAGE

IMAGE: Executive vice-chair of emergency medicine, University of Pittsburgh School of Medicine
view more 

Credit: UPMC

PITTSBURGH, July 28, 2020 – A team of University of Pittsburgh, Michigan Medicine, Medical University of South Carolina and Stanford Medicine. researchers recently were awarded funds from the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), totaling more than $7 million to collaboratively study the role of convalescent plasma in mitigating symptoms of COVID-19 in patients with mild illness and preventing the progression of the disease from mild to severe.

Convalescent plasma is derived from blood donated by persons who have already had COVID-19 and have recovered. Convalescent plasma contains antibodies that can bind to the virus that causes COVID-19 and neutralize it. Currently, convalescent plasma can be given as a treatment for patients in the hospital with severe or life-threatening COVID-19, a process called passive immunization.

Conducted as part of the NHLBI Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS) initiative, the Clinical Trial of COVID-19 Convalescent Plasma of Outpatients (C3PO) aims to evaluate whether passive immunization can be a safe and efficacious therapy in preventing the progression from mild to severe or critical COVID-19 illness and to understand the immunologic impact of anti-SARS-CoV-2 antibodies on the disease after passive immunization.

“We are going to recruit patients who are at high risk for developing severe illness and may be most likely to benefit from a preventative treatment, such as patients over 50, those with heart disease, lung disease or diabetes and patients who are immunocompromised,” said Clifton Callaway, M.D., Ph.D., executive vice-chair of emergency medicine at the University of Pittsburgh.

“We think that convalescent plasma has the best chance of being effective if used when patients are just starting to show symptoms [in order to] decrease viral replication and the resulting severe inflammatory response that can be so damaging,” said Simone Glynn, M.D.,M.P.H., chief of the NHLBI’s Blood Epidemiology and Clinical Therapeutics branch. “What we want to find out is whether this plasma is effective enough to keep these at-risk patients from progressing to a point where they need hospitalization.”

According to the World Health Organization, more than 8 million people worldwide have been diagnosed with COVID-19, the respiratory illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and more than 646,000 have died from the disease.

C3PO will study 600 COVID-19 patients at 50 U.S. medical centers who present to the emergency department with mild illness.

###

This research will be funded by the National Heart, Lung, and Blood Institute (NHLBI) and the Biomedical Advance Research and Development Authority (BARDA) as a sub award under the NHLBI Other Transaction Award 1OT2HL156812-01.

To read this release online or share it, visit https://www.upmc.com/media/news/072820-nih-pitt-c3po.

About the University of Pittsburgh Schools of the Health Sciences

The University of Pittsburgh Schools of the Health Sciences include the schools of Medicine, Nursing, Dental Medicine, Pharmacy, Health and Rehabilitation Sciences and the Graduate School of Public Health. The schools serve as the academic partner to the UPMC (University of Pittsburgh Medical Center). Together, their combined mission is to train tomorrow’s health care specialists and biomedical scientists, engage in groundbreaking research that will advance understanding of the causes and treatments of disease and participate in the delivery of outstanding patient care. Since 1998, Pitt and its affiliated university faculty have ranked among the top 10 educational institutions in grant support from the National Institutes of Health. For additional information about the Schools of the Health Sciences, please visit http://www.health.pitt.edu.

http://www.upmc.com/media

Severskiy.com

Similar Articles

Comments

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Study: Effectiveness of cloth masks depends on type of covering

Months into the COVID-19 pandemic, wearing a mask while out in public has become the recommended practice. However, many still question the effectiveness of...

Archaeology: Cooling of Earth caused by eruptions, not meteors

IMAGE: Workers excavating Hall's Cave in Central Texas ...

Nanotechnology: Sharing a secret…the quantum way

IMAGE: An artistic impression sharing a secret using structured...

Medicine: Insight on novel genetic approaches to metabolic liver diseases

DETROIT - Diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) are all common diseases that can lead to serious health implications. NAFLD affects over...

Diseases: Targetable biological mechanisms implicated in emergent psychiatric conditions associated with SARS-CoV-2

What The Viewpoint Says: Targetable biological mechanisms implicated in emergent psychiatric conditions associated with SARS-CoV-2 infection are discussed in this Viewpoint. Authors: Teodor T. Postolache, M.D., of...

Science: Policies to mitigate wildfire impacts have public health implications, amplified amid COVID

As the western United States enters the 2020 wildfire season with anticipated above normal significant fire potential, a new report from Physicians, Scientists,...